Vesugen (also designated T-38 in the Khavinson research program) is a synthetic tripeptide bioregulator with the amino acid sequence Lysine-Glutamic Acid-Aspartic Acid (Lys-Glu-Asp, abbreviated KED). It belongs to the Khavinson peptide series\u2014a family of short-chain peptides developed through research on tissue-specific bioregulators at the St. Petersburg Institute of Bioregulation and Gerontology. Researchers originally identified Vesugen from vascular wall tissue extracts and designed it as a synthetic analog for investigating vascular endothelial function and regulation.<\/p>\n
As a tripeptide\u2014a peptide composed of exactly three amino acids\u2014Vesugen has attracted research interest for its proposed ability to penetrate cellular and nuclear membranes to interact directly with DNA and histone proteins, thereby modulating gene expression through epigenetic mechanisms. Researchers classify Vesugen as a tissue-specific bioregulator targeting vascular endothelium, meaning it may influence cellular processes through chromatin-level gene regulation rather than through classical receptor-mediated signaling. For those looking to buy Vesugen in Switzerland<\/strong>, Core Peptides offers high-quality research-grade material for laboratory applications.<\/p>\n Vesugen represents a well-characterized peptide bioregulator within the Khavinson research program, specifically designated as a vascular-targeted bioregulator. The peptide’s design\u2014a simple tripeptide sequence of lysine, glutamic acid, and aspartic acid\u2014belies its proposed biological activity. Researchers have investigated Vesugen primarily for its tissue-specific effects on vascular endothelial-derived experimental systems, with implications for understanding endothelial cell function, vascular tissue maintenance, and age-related vascular changes.<\/p>\n Research interest in Vesugen centers on its ability to modulate gene expression and support endothelial cell homeostasis in the vascular system. Studies have demonstrated that Vesugen penetrates cell nuclei and interacts with DNA, potentially modulating gene expression linked to vascular endothelial function. Specifically, Vesugen may influence the expression of genes involved in endothelial cell proliferation, SIRT1 modulation, and vascular tone regulation.<\/p>\n When researchers choose to buy Vesugen in Switzerland<\/strong> for laboratory studies, they gain access to a compound that may help elucidate mechanisms of vascular endothelial bioregulation, gene expression modulation, and epigenetic regulation at the molecular level.<\/p>\n Vesugen exerts its proposed biological effects through multiple interconnected pathways, including chromatin-level gene regulation, DNA interaction, and tissue-specific gene modulation. The peptide’s mechanism involves several well-characterized steps.<\/p>\n Vesugen’s primary proposed mechanism involves penetration of cellular and nuclear membranes to interact directly with DNA. Research suggests that Vesugen may bind to specific DNA sequences in the minor groove of DNA, forming hydrogen bonds with specific DNA base pairs. This interaction may influence chromatin condensation states and gene expression patterns.<\/p>\n Vesugen is studied as a vascular-directed short-peptide probe, used to examine how a minimal defined peptide signal influences transcriptional, proteomic, and proliferation endpoints in vascular-derived cell populations.<\/p>\n Research indicates that Vesugen may stimulate the proliferation marker Ki-67, which declines with age, and may reduce apoptosis (decreased p53), thereby supporting endothelial cell renewal and vascular-tissue gene-expression programs. This mechanism may be particularly relevant in addressing age-related vascular function problems.<\/p>\n Beyond its vascular applications, Vesugen has also been explored for its neuroprotective and geroprotective consequences. Studies have examined its effects on neuron survival and morphology, suggesting its possible role in combating neurodegenerative diseases and enhancing neuroplasticity. In a 5xFAD Alzheimer’s mouse model study, KED was co-tested with EDR (Pinealon), with molecular docking predicting KED binding to promoter regions of AD-relevant genes including CASP3, NES, GAP43, APOE, SOD2, PPARA, and PPARG.<\/p>\n Researchers who buy Vesugen in Switzerland<\/strong> for research purposes can investigate these mechanisms across diverse experimental models of vascular biology, endothelial function, and gene expression modulation.<\/p>\n Researchers study Vesugen primarily for its potential relevance to vascular endothelial biology, cardiovascular tissue maintenance, and age-related vascular changes. The peptide’s ability to modulate gene expression and support endothelial cell homeostasis makes it a valuable tool for understanding the molecular basis of tissue-specific bioregulation and epigenetic mechanisms.<\/p>\n Vesugen has been investigated in the context of vascular and endothelial function. The peptide is specifically designed to support vascular endothelial cells, with research indicating potential applications for cardiovascular tissue maintenance in aging. Studies have explored its effects on endothelial cell proliferation, vascular tone regulation, and tissue blood flow.<\/p>\n Moreover, researchers study Vesugen in the context of age-related vascular changes. As vascular endothelial function naturally declines with age, understanding mechanisms that support tissue homeostasis has become increasingly important. Vesugen represents one well-documented avenue of research inquiry in this area.<\/p>\n Researchers who buy Vesugen in Switzerland<\/strong> from Core Peptides can incorporate this peptide into their studies on vascular endothelial bioregulation, gene expression modulation, and age-related vascular research.<\/p>\n Researchers have conducted scientific studies on Vesugen in both in vitro and preclinical settings, deriving evidence from cell cultures, preclinical models, and limited clinical research. The peptide originates from the Khavinson research program, which has investigated tissue-specific peptide bioregulators for several decades.<\/p>\n In vitro studies using fluorescence-labeled peptides have demonstrated that Vesugen penetrates cell nuclei and interacts with DNA. Research has shown that Vesugen may bind to specific DNA sequences in the minor groove, forming hydrogen bonds with specific DNA base pairs.<\/p>\n Furthermore, research has demonstrated that Vesugen interacts with chromatin and may modulate gene expression linked to vascular endothelial function. The peptide’s ability to penetrate both cell and nuclear membranes supports its proposed mechanism of direct nuclear interaction.<\/p>\n Studies have shown that Vesugen stimulates the proliferation marker Ki-67 (which declines with age) and reduces apoptosis (decreased p53), used experimentally to study endothelial cell renewal and vascular-tissue gene-expression programs.<\/p>\n In animal models, researchers have investigated Vesugen’s effects on vascular function and aging. The vasoprotective effect of Vesugen, previously revealed in elder people, can be manifested through epigenetic regulation of the Ki-67 gene expression.<\/p>\n In a 5xFAD Alzheimer’s mouse model study, KED was co-tested with EDR (Pinealon). Molecular docking predicted KED and EDR binding to promoter regions of AD-relevant genes including CASP3, NES, GAP43, APOE, SOD2, PPARA, and PPARG.<\/p>\n Research has also explored Vesugen’s effects on endothelial cell proliferation and differentiation in vascular tissue studies.<\/p>\n Vesugen has limited human clinical evidence. No published clinical studies were found on PubMed for Vesugen. Evidence is limited to preclinical research or theoretical mechanisms. The peptide has not achieved pharmaceutical registration in Western countries and is primarily available as a research compound. No clinical trials are registered on ClinicalTrials.gov, and no Western regulatory agency has evaluated Vesugen for any therapeutic indication.<\/p>\n Nevertheless, researchers should note that Vesugen is supplied for laboratory research purposes only. Scientists who buy Vesugen in Switzerland<\/strong> should remain aware of these evidence considerations.<\/p>\nVesugen Research Overview<\/h2>\n
How Does Vesugen Work?<\/h2>\n
DNA Binding and Epigenetic Regulation<\/h3>\n
Endothelial Cell Proliferation and Ki-67 Regulation<\/h3>\n
Neuroprotective and Geroprotective Effects<\/h3>\n
Why Is Vesugen Studied?<\/h2>\n
Vesugen Research Areas<\/h2>\n
\n\n
\n \nResearch Area<\/th>\n Description<\/th>\n<\/tr>\n<\/thead>\n \n Vascular Endothelial Function<\/strong><\/td>\n Investigating Vesugen’s effects on endothelial cell proliferation and vascular tissue maintenance<\/td>\n<\/tr>\n \n Gene Expression Modulation<\/strong><\/td>\n Studying Vesugen’s interaction with DNA and modulation of gene expression in vascular cells<\/td>\n<\/tr>\n \n Epigenetic Regulation<\/strong><\/td>\n Exploring Vesugen’s proposed epigenetic mechanisms of gene expression modulation<\/td>\n<\/tr>\n \n Cardiovascular Research<\/strong><\/td>\n Examining Vesugen’s effects on cardiovascular tissue and vascular tone regulation<\/td>\n<\/tr>\n \n Endothelial Cell Proliferation<\/strong><\/td>\n Investigating Vesugen’s stimulation of Ki-67 and endothelial cell renewal<\/td>\n<\/tr>\n \n Neuroprotection<\/strong><\/td>\n Preclinical research into Vesugen’s neuroprotective effects in neuronal models<\/td>\n<\/tr>\n \n SIRT1 Modulation<\/strong><\/td>\n Studying Vesugen’s effects on SIRT1 expression and protein synthesis<\/td>\n<\/tr>\n \n Age-Related Vascular Research<\/strong><\/td>\n Exploring Vesugen’s potential relevance to age-related vascular changes<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n Scientific Research on Vesugen<\/h2>\n
In Vitro Evidence<\/h3>\n
Preclinical Studies<\/h3>\n
Human Research<\/h3>\n
Vesugen Compared With Related Peptides<\/h2>\n